Ablynx appoints Dr. Andreas Menrad as Chief Scientific Officer
Ablynx announced that it has appointed Dr Andreas Menrad as its Chief Scientific Officer.
Dr Menrad has over 20 years experience in the pharmaceutical and biotech industry, with significant expertise in drug discovery and the successful progression of lead candidates into pre-clinical development. He will head up the research activities, be responsible for the ongoing development of the Nanobody® platform, and identify and prioritise new therapeutic programmes that Ablynx will take forward either on its own or with partners to help continue building the rapidly growing portfolio of Nanobody development candidates.
Prior to joining Ablynx, Dr Menrad was at Genzyme for five years, where since 2011 he held the position of General Manager and Vice President of Antibody Therapeutics. Previously he has also held senior research positions with Schering AG.
Dr Menrad received his Ph.D. in immunology from the University Stuttgart in 1989. He then took a post-doctoral position at The Wistar Institute Cancer Center in Pennsylvania, USA.
Most read news
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.